Q32 Bio (QTTB) Set to Post Quarterly Earnings on Thursday

Q32 Bio (NASDAQ:QTTB) is expected to release its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.36) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.

Q32 Bio (NASDAQ:QTTB) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.07. On average, analysts expect Q32 Bio to post ($1.43) EPS for the current fiscal year and ($1.88) EPS for the next fiscal year.

Q32 Bio Stock Performance

NASDAQ:QTTB opened at $9.34 on Tuesday. The firm has a 50-day simple moving average of $9.60 and a 200-day simple moving average of $9.38. Q32 Bio has a one year low of $1.90 and a one year high of $23.57. The firm has a market cap of $278.05 million, a P/E ratio of 3.72 and a beta of 0.45.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on QTTB. Morgan Stanley began coverage on shares of Q32 Bio in a report on Monday, August 24th. They set an “overweight” rating and a $34.00 price objective on the stock. Oppenheimer reissued an “outperform” rating on shares of Q32 Bio in a research note on Thursday, October 1st. Jefferies Financial Group assumed coverage on Q32 Bio in a report on Monday, September 28th. They set a “buy” rating and a $29.00 target price for the company. Weiss Ratings raised Q32 Bio from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, August 21st. Finally, Mizuho raised Q32 Bio to a “strong-buy” rating in a research report on Monday, September 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Q32 Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.17.

Insiders Place Their Bets

In other news, insider Shelia M. Violette sold 2,798 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $46,334.88. Following the sale, the insider directly owned 127,771 shares in the company, valued at approximately $2,115,887.76. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Lee Kalowski sold 3,972 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $65,776.32. Following the completion of the sale, the chief financial officer owned 138,471 shares in the company, valued at $2,293,079.76. This represents a 2.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 22,054 shares of company stock worth $320,397. 34.46% of the stock is owned by corporate insiders.

About Q32 Bio

Q32 Bio Inc (NASDAQ: QTTB) is a clinical-stage biotechnology company focused on developing biologic therapies for diseases associated with immune-system dysfunction. The company’s research programs are designed to restore immune balance rather than broadly suppress immune activity.

Q32 Bio’s lead product candidate is bempikibart, formerly known as ADX-914, a fully human monoclonal antibody that targets activin receptor type IIA (ActRIIA). The company has evaluated bempikibart in inflammatory and autoimmune conditions, including atopic dermatitis and alopecia areata.

The company also has pursued additional immunology programs, including therapies intended to address complement-mediated disease.